Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
R&D

Hong Kong Researchers Explore TES for Depression and Alzheimer’s Treatment

Fineline Cube Jul 11, 2022

Researchers at The University of Hong Kong’s Li Ka Shing Faculty of Medicine (HKUMed) and...

Company

CASI Pharmaceuticals Invests in Precision Immune Therapeutics for CID-103 Development

Fineline Cube Jul 11, 2022

US-based CASI Pharmaceuticals Inc. (NASDAQ: CASI) announced the completion of a financing round for China’s...

Company

Sinopharm in Talks to Acquire BBI Life Sciences in USD 1B+ Deal

Fineline Cube Jul 11, 2022

China National Pharmaceutical Group Co., Ltd (Sinopharm) is reportedly considering a bid to acquire Shanghai-based...

Company Legal / IP

Acer Therapeutics and Relief Therapeutics Awarded China Patent for ACER-001

Fineline Cube Jul 11, 2022

US-based Acer Therapeutics Inc. (Nasdaq: ACER) and Swiss partner Relief Therapeutics Holding SA (SWX: RLF)...

Company Deals

Bangbang Robot Raises USD 14.9M in Series B to Expand Mobility Tech

Fineline Cube Jul 11, 2022

Shanghai-based Bangbang Robot Co., Ltd, a developer of assisted mobility technology, has raised nearly RMB...

Company Drug

OBI Pharma Halts OBI 888 Trial Over Manufacturing Costs, Shifts Focus to Globo H ADC

Fineline Cube Jul 11, 2022

Taiwan-based OBI Pharma (TPEx: 4174) announced the discontinuation of a Phase I/II trial for its...

Company Drug

Hengrui Medicine’s SHR8554 Accepted for NMPA Review in Postoperative Pain

Fineline Cube Jul 11, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that its market filing for SHR8554,...

R&D

Insilico Medicine Identifies Novel ALS Therapeutic Targets via AI Platform PandaOmics

Fineline Cube Jul 11, 2022

China-based Insilico Medicine announced the identification of multiple novel therapeutic targets for amyotrophic lateral sclerosis...

Company Drug

CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review

Fineline Cube Jul 11, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...

Company Drug

Gan & Lee Pharmaceuticals’ GZR4 Ultra-Long-Acting Insulin Receives Clinical Trial Approval

Fineline Cube Jul 11, 2022

China-based Gan & Lee Pharmaceuticals (SHA: 603087) announced that its Category 1 therapeutic biologic product...

Company Deals

Aden Secures USD 29.8M Series B+ Funding to Expand DRG/DIP Solutions

Fineline Cube Jul 11, 2022

Beijing-based AI medical big data firm Aden, also known as Yading Data, has raised RMB...

Policy / Regulatory

NMPA Issues New Vaccine Manufacturing and Distribution Rules

Fineline Cube Jul 11, 2022

China’s National Medical Products Administration (NMPA) has released the “Vaccine Manufacturing and Distribution Management Measures,”...

Company Drug

VivaVision Biotech’s VVN539 Enters Phase II Trial for Open-Angle Glaucoma in US

Fineline Cube Jul 11, 2022

China’s VivaVision Biotech Inc. announced the first patient enrollment in a Phase II clinical study...

Company Deals

Science Sun Pharma and Mabworks Biotech Sign Strategic Cooperation Pact

Fineline Cube Jul 11, 2022

Beijing Science Sun Pharmaceutical Co., Ltd (SHE: 300485) announced a strategic cooperation framework agreement with...

Company Deals

Hangzhou DAC Bio Partners with Janssen on ADC Development Deal

Fineline Cube Jul 11, 2022

China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...

Policy / Regulatory

NHSA Sets 2022 Goals for Basic Medical Insurance Funding and Reforms

Fineline Cube Jul 8, 2022

The National Healthcare Security Administration (NHSA), Ministry of Finance (MOF), and State Taxation Administration (STA)...

Company Drug

Neurophth’s NR082 Gene Therapy Receives BTD for Leber Hereditary Optic Neuropathy

Fineline Cube Jul 8, 2022

China’s Center for Drug Evaluation (CDE) has awarded breakthrough therapy designation (BTD) to Wuhan Neurophth...

Company Drug

Biotheus Inc.’s PM1009 Bispecific Antibody Enters Clinical Trial Review for Solid Tumors

Fineline Cube Jul 8, 2022

China-based Biotheus Inc. announced that its clinical trial filing for PM1009, a bispecific antibody (BsAb)...

Company Deals

Rainmed Medical Makes IPO Debut on Hong Kong Exchange with Valuation Over USD 764M

Fineline Cube Jul 8, 2022

Suzhou Rainmed Medical Technology Co., Ltd, a China-based vascular intervention robot manufacturer, has completed its...

Company Deals

MicuRx Pharmaceuticals Approved for STAR Market IPO by CSRC

Fineline Cube Jul 8, 2022

The China Securities Regulatory Commission (CSRC) has approved the initial public offering (IPO) of Sino-US...

Posts pagination

1 … 678 679 680 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.